201 related articles for article (PubMed ID: 30364293)
1. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study.
Scatena C; Roncella M; Di Paolo A; Aretini P; Menicagli M; Fanelli G; Marini C; Mazzanti CM; Ghilli M; Sotgia F; Lisanti MP; Naccarato AG
Front Oncol; 2018; 8():452. PubMed ID: 30364293
[No Abstract] [Full Text] [Related]
2. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease.
Lamb R; Ozsvari B; Lisanti CL; Tanowitz HB; Howell A; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2015 Mar; 6(7):4569-84. PubMed ID: 25625193
[TBL] [Abstract][Full Text] [Related]
3. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs).
Fiorillo M; Tóth F; Sotgia F; Lisanti MP
Aging (Albany NY); 2019 Apr; 11(8):2202-2216. PubMed ID: 31002656
[TBL] [Abstract][Full Text] [Related]
4. A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.
Sotgia F; Ozsvari B; Fiorillo M; De Francesco EM; Bonuccelli G; Lisanti MP
Cell Cycle; 2018; 17(17):2091-2100. PubMed ID: 30257595
[TBL] [Abstract][Full Text] [Related]
5. Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.
Parte SC; Batra SK; Kakar SS
J Ovarian Res; 2018 Aug; 11(1):69. PubMed ID: 30121075
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells.
De Luca A; Fiorillo M; Peiris-Pagès M; Ozsvari B; Smith DL; Sanchez-Alvarez R; Martinez-Outschoorn UE; Cappello AR; Pezzi V; Lisanti MP; Sotgia F
Oncotarget; 2015 Jun; 6(17):14777-95. PubMed ID: 26087310
[TBL] [Abstract][Full Text] [Related]
7. Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy.
De Francesco EM; Maggiolini M; Tanowitz HB; Sotgia F; Lisanti MP
Oncotarget; 2017 Aug; 8(34):56126-56142. PubMed ID: 28915578
[TBL] [Abstract][Full Text] [Related]
8. Doxycycline Induces Apoptosis and Inhibits Proliferation and Invasion of Human Cervical Carcinoma Stem Cells.
Yang B; Lu Y; Zhang A; Zhou A; Zhang L; Zhang L; Gao L; Zang Y; Tang X; Sun L
PLoS One; 2015; 10(6):e0129138. PubMed ID: 26111245
[TBL] [Abstract][Full Text] [Related]
9. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy.
Lamb R; Fiorillo M; Chadwick A; Ozsvari B; Reeves KJ; Smith DL; Clarke RB; Howell SJ; Cappello AR; Martinez-Outschoorn UE; Peiris-Pagès M; Sotgia F; Lisanti MP
Oncotarget; 2015 Jun; 6(16):14005-25. PubMed ID: 26087309
[TBL] [Abstract][Full Text] [Related]
10. Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine).
De Francesco EM; Ózsvári B; Sotgia F; Lisanti MP
Front Oncol; 2019; 9():615. PubMed ID: 31440463
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
13. Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs).
De Francesco EM; Bonuccelli G; Maggiolini M; Sotgia F; Lisanti MP
Oncotarget; 2017 Sep; 8(40):67269-67286. PubMed ID: 28978032
[TBL] [Abstract][Full Text] [Related]
14. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
16. A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis.
Ozsvari B; Sotgia F; Lisanti MP
Aging (Albany NY); 2017 Oct; 9(10):2098-2116. PubMed ID: 29080556
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
18. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.
Neumeister V; Agarwal S; Bordeaux J; Camp RL; Rimm DL
Am J Pathol; 2010 May; 176(5):2131-8. PubMed ID: 20228222
[TBL] [Abstract][Full Text] [Related]
19. Doxycycline targets aldehyde dehydrogenase‑positive breast cancer stem cells.
Lin CC; Lo MC; Moody RR; Stevers NO; Tinsley SL; Sun D
Oncol Rep; 2018 Jun; 39(6):3041-3047. PubMed ID: 29620216
[TBL] [Abstract][Full Text] [Related]
20. Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment.
Pershina O; Ermakova N; Pakhomova A; Widera D; Pan E; Zhukova M; Slonimskaya E; Morozov SG; Kubatiev A; Dygai A; Skurikhin EG
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]